Welcome to our dedicated page for LOAC news (Ticker: LOAC), a resource for investors and traders seeking the latest updates and insights on LOAC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LOAC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LOAC's position in the market.
On March 18, 2021, Longevity Acquisition Corporation (NASDAQ: LOAC) announced the successful outcome of its special shareholder meeting held on March 17, 2021. Shareholders approved the merger with 4d pharma plc, as per the merger agreement established on October 21, 2020. 4d pharma specializes in Live Biotherapeutics, with several ongoing clinical programs. The merger aims to enhance market presence and operational synergies, paving the way for 4d pharma's anticipated NASDAQ listing under the ticker 'LBPS' in early 2021, pending shareholder approvals and SEC review.
Longevity Acquisition Corporation (NASDAQ: LOAC) announced a collaboration with 4D pharma for a clinical trial evaluating BAVENCIO® (avelumab) in combination with MRx0518 for patients with locally advanced or metastatic urothelial carcinoma. This trial aims to assess the efficacy of MRx0518 as a maintenance therapy following first-line chemotherapy. 4D pharma is already conducting multiple clinical evaluations for MRx0518, a Live Biotherapeutic product. The collaboration marks a significant step in their effort to enhance treatment options for cancer patients.
Longevity Acquisition Corporation (NASDAQ: LOAC) announced progress by its merger target, 4D pharma, in the development of its lead cancer treatment candidate, MRx0518. The candidate exhibited promising safety and efficacy data in ongoing trials, including a combination study with KEYTRUDA. With patient enrollment expanding across various malignancies, 4D pharma anticipates significant clinical data generation over the next year. The merger is set to bring innovative Live Biotherapeutic products to market, with a NASDAQ listing expected in early 2021, pending shareholder approval.
Longevity Acquisition Corporation (NASDAQ: LOAC) announced on December 10, 2020, that it has regained compliance with Nasdaq's Minimum Public Holders Rule after demonstrating it has over 300 public holders. This follows a prior notification from Nasdaq regarding non-compliance as disclosed in LOAC's September 2, 2020, report. LOAC is a special purpose acquisition company considering a merger with 4D Pharma PLC. The company aims for compliance to maintain its listing status on the Nasdaq Capital Market, securing its position for future business endeavors.
Longevity Acquisition Corporation (NASDAQ: LOAC) has announced an extension for completing its business combination with 4D Pharma PLC from November 30, 2020 to May 29, 2021. The extension was approved by shareholders during a special meeting held on November 20, 2020, allowing more time for the necessary conditions and filings to be satisfied. This includes 4D's registration statement to facilitate the trading of its American Depositary Shares on NASDAQ. The merger agreement was initially disclosed on October 22, 2020.
Longevity Acquisition Corporation (NASDAQ: LOAC) announced plans to extend the deadline for its initial business combination from November 30, 2020, to May 29, 2021, if approved by shareholders. For Remaining Shares not redeemed during this extension, LOAC will increase its cash contribution from $0.025 to $0.05 per share monthly to the trust account. This decision reflects LOAC's commitment to securing a target for acquisition and providing additional returns to shareholders during the extension period.
Longevity Acquisition Corporation (NASDAQ: LOAC) has signed a definitive merger agreement with 4D pharma PLC (AIM: DDDD). Post-merger, LOAC shareholders will receive American Depositary Shares (ADSs) of 4D and become a fully owned subsidiary of 4D. The merger aims to enhance 4D's presence in the US capital markets and access a wider pool of investment. The transaction details include a conversion of LOAC shares into 4D shares with LOAC shareholders anticipated to own around 13.1% of the combined company. The merger is subject to shareholder approvals and customary closing conditions.
